{"DataElement":{"publicId":"2649486","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 051 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_051_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2644269","version":"1","preferredName":"051 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 051 protocol.","longName":"051_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Does the participant have biopsy-proven KS involving the skin, lymph nodes, oral cavity, GI tract and/or lungs (GI and pulmonary involvement must be asymptomatic or minimally symptomatic and not require systemic cytotoxic therapy)","valueDescription":"Does the participant have biopsy-proven KS involving the skin, lymph nodes, oral cavity, GI tract and/or lungs (GI and pulmonary involvement must be asymptomatic or minimally symptomatic and not require systemic cytotoxic therapy)","ValueMeaning":{"publicId":"2649456","version":"1","preferredName":"Does the participant have biopsy-proven KS involving the skin, lymph nodes, oral cavity, GI tract and/or lungs (GI and pulmonary involvement must be asymptomatic or minimally symptomatic and not require systemic cytotoxic therapy)","longName":"2649456","preferredDefinition":"Does the participant have biopsy-proven KS involving the skin, lymph nodes, oral cavity, GI tract and/or lungs (GI and pulmonary involvement must be asymptomatic or minimally symptomatic and not require systemic cytotoxic therapy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32652E60-3757-3C62-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7BCD-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","valueDescription":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","ValueMeaning":{"publicId":"2649457","version":"1","preferredName":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","longName":"2649457","preferredDefinition":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test, or a detectable blood level of HIV RNA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653064-8231-372A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7BDF-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Karnofsky Performance Status (must be > 60%)","valueDescription":"Karnofsky Performance Status (must be > 60%)","ValueMeaning":{"publicId":"2580739","version":"1","preferredName":"Karnofsky Performance Status (must be > 60%)","longName":"2580739","preferredDefinition":"Karnofsky Performance Status (must be > 60%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7BEB-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"If the participant is female, did she have a negative pregnancy test within 72 hours before initiation of study drug dosing","valueDescription":"If the participant is female, did she have a negative pregnancy test within 72 hours before initiation of study drug dosing","ValueMeaning":{"publicId":"2649458","version":"1","preferredName":"If the participant is female, did she have a negative pregnancy test within 72 hours before initiation of study drug dosing","longName":"2649458","preferredDefinition":"If the participant is female, did she have a negative pregnancy test within 72 hours before initiation of study drug dosing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653351-E32A-3C04-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7BFC-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant, male or female, of reproductive age, agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","valueDescription":"Does the participant, male or female, of reproductive age, agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","ValueMeaning":{"publicId":"2649459","version":"1","preferredName":"Does the participant, male or female, of reproductive age, agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","longName":"2649459","preferredDefinition":"Does the participant, male or female, of reproductive age, agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651C02-21C8-3BA3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C0E-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","valueDescription":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","ValueMeaning":{"publicId":"2649462","version":"1","preferredName":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","longName":"2649462","preferredDefinition":"Does the participant have the following laboratory parameters within 21 days prior to study entry: Hemoglobin >= 8.0 gm/dL; Absolute neutrophil count >= 1000 cells/mm3; Platelet count >= 75,000/mm3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651845-D98B-3B9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"326547FD-96DC-3EA8-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"GFR > 40 mL/min (calculated by the Cockcroft-Gault equation), calculated as follows For males = 140 - age [years]) x (body weight [kg]) / (72) x (serum creatinine [mg/dL]; For females = 0.85 x male value","valueDescription":"GFR > 40 mL/min (calculated by the Cockcroft-Gault equation), calculated as follows For males = 140 - age [years]) x (body weight [kg]) / (72) x (serum creatinine [mg/dL]; For females = 0.85 x male value","ValueMeaning":{"publicId":"2649463","version":"1","preferredName":"GFR > 40 mL/min (calculated by the Cockcroft-Gault equation), calculated as follows For males = 140 - age [years]) x (body weight [kg]) / (72) x (serum creatinine [mg/dL]; For females = 0.85 x male value","longName":"2649463","preferredDefinition":"GFR > 40 mL/min (calculated by the Cockcroft-Gault equation), calculated as follows For males = 140 - age [years]) x (body weight [kg]) / (72) x (serum creatinine [mg/dL]; For females = 0.85 x male value","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32654166-B77E-3C12-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"326547FD-96EE-3EA8-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have a Total bilirubin <= 1.5 times upper limit of normal (ULN)","valueDescription":"Does the participant have a Total bilirubin <= 1.5 times upper limit of normal (ULN)","ValueMeaning":{"publicId":"2649466","version":"1","preferredName":"Does the participant have a Total bilirubin <= 1.5 times upper limit of normal (ULN)","longName":"2649466","preferredDefinition":"Does the participant have a Total bilirubin <= 1.5 times upper limit of normal (ULN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653064-8241-372A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"326547FD-9700-3EA8-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have a AST (SGOT) and ALT (SGPT) <=2.5 times the ULN","valueDescription":"Does the participant have a AST (SGOT) and ALT (SGPT) <=2.5 times the ULN","ValueMeaning":{"publicId":"2649467","version":"1","preferredName":"Does the participant have a AST (SGOT) and ALT (SGPT) <=2.5 times the ULN","longName":"2649467","preferredDefinition":"Does the participant have a AST (SGOT) and ALT (SGPT) <=2.5 times the ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32652820-DE87-3C0E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"326547FD-9712-3EA8-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have a fasting triglyceride level of <= 400 mg/dL (4.5 mmol/L), and a total cholesterol level of <= 300 mg/dL (7.8 mmol/L)","valueDescription":"Does the participant have a fasting triglyceride level of <= 400 mg/dL (4.5 mmol/L), and a total cholesterol level of <= 300 mg/dL (7.8 mmol/L)","ValueMeaning":{"publicId":"2649468","version":"1","preferredName":"Does the participant have a fasting triglyceride level of <= 400 mg/dL (4.5 mmol/L), and a total cholesterol level of <= 300 mg/dL (7.8 mmol/L)","longName":"2649468","preferredDefinition":"Does the participant have a fasting triglyceride level of <= 400 mg/dL (4.5 mmol/L), and a total cholesterol level of <= 300 mg/dL (7.8 mmol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32652E60-3767-3C62-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"326547FD-9724-3EA8-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Regarding the participant's spot urine protein: Is the creatinine ratio <= 0.5 and/or proteinuria <= 500 mg/day","valueDescription":"Regarding the participant's spot urine protein: Is the creatinine ratio <= 0.5 and/or proteinuria <= 500 mg/day","ValueMeaning":{"publicId":"2649469","version":"1","preferredName":"Regarding the participant's spot urine protein: Is the creatinine ratio <= 0.5 and/or proteinuria <= 500 mg/day","longName":"2649469","preferredDefinition":"Regarding the participant's spot urine protein: Is the creatinine ratio <= 0.5 and/or proteinuria <= 500 mg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32654D65-BED6-3F71-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C20-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Is the participant's life expectancy 3 months or more","valueDescription":"Is the participant's life expectancy 3 months or more","ValueMeaning":{"publicId":"2649470","version":"1","preferredName":"Is the participant's life expectancy 3 months or more","longName":"2649470","preferredDefinition":"Is the participant's life expectancy 3 months or more","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651F9F-1D26-3BDA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C32-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Participant's age (in years)","valueDescription":"Participant's age (in years)","ValueMeaning":{"publicId":"2649471","version":"1","preferredName":"Participant's age (in years)","longName":"2649471","preferredDefinition":"Participant's age (in years)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"326557B2-97F1-3BD4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C44-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Does the participant have the ability and willingness to give informed consent","valueDescription":"Does the participant have the ability and willingness to give informed consent","ValueMeaning":{"publicId":"2649472","version":"1","preferredName":"Does the participant have the ability and willingness to give informed consent","longName":"2649472","preferredDefinition":"Does the participant have the ability and willingness to give informed consent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32655A77-933F-3C34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C56-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Date informed consent obtained","valueDescription":"Date informed consent obtained","ValueMeaning":{"publicId":"2580745","version":"1","preferredName":"Date informed consent obtained","longName":"2580745","preferredDefinition":"Date informed consent obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651DF6-7C62-3C79-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","valueDescription":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","ValueMeaning":{"publicId":"2649473","version":"1","preferredName":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","longName":"2649473","preferredDefinition":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651AA4-03DC-3BA1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651F9F-1D3D-3BDA-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Has the participant been on stable anti-retroviral therapy for at least 12 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks of starting study drug","valueDescription":"Has the participant been on stable anti-retroviral therapy for at least 12 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks of starting study drug","ValueMeaning":{"publicId":"2649474","version":"1","preferredName":"Has the participant been on stable anti-retroviral therapy for at least 12 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks of starting study drug","longName":"2649474","preferredDefinition":"Has the participant been on stable anti-retroviral therapy for at least 12 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks of starting study drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"326561CA-7E98-3DD1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651F9F-1D4F-3BDA-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Has the participant had no prior treatment with rapamycin","valueDescription":"Has the participant had no prior treatment with rapamycin","ValueMeaning":{"publicId":"2649475","version":"1","preferredName":"Has the participant had no prior treatment with rapamycin","longName":"2649475","preferredDefinition":"Has the participant had no prior treatment with rapamycin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653351-E33A-3C04-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651F9F-1D61-3BDA-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Is the participant's CD4 count >50 cells/uL and serum HIV RNA level <400 copies/mL","valueDescription":"Is the participant's CD4 count >50 cells/uL and serum HIV RNA level <400 copies/mL","ValueMeaning":{"publicId":"2649476","version":"1","preferredName":"Is the participant's CD4 count >50 cells/uL and serum HIV RNA level <400 copies/mL","longName":"2649476","preferredDefinition":"Is the participant's CD4 count >50 cells/uL and serum HIV RNA level <400 copies/mL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3265654A-CD9A-3DC5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32651F9F-1D73-3BDA-E044-0003BA3F9857","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"ONEDATA","dateModified":"2007-06-08","deletedIndicator":"No"},{"value":"Urine protein","valueDescription":"Urine Protein Measurement","ValueMeaning":{"publicId":"6517257","version":"1","preferredName":"Urine Protein Measurement","longName":"6517257","preferredDefinition":"The determination of the amount of protein present in a urine sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urine Protein Measurement","conceptCode":"C74760","definition":"The determination of the amount of protein present in a urine sample.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7895D67B-3E00-2E34-E053-F662850A08F6","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-19","modifiedBy":"ONEDATA","dateModified":"2018-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7895D67B-3E19-2E34-E053-F662850A08F6","beginDate":"2018-10-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-19","modifiedBy":"ONEDATA","dateModified":"2018-10-19","deletedIndicator":"No"},{"value":"Urine Protein/Creatinine Ratio","valueDescription":"Urine Protein Measurement Creatinine Ratio","ValueMeaning":{"publicId":"6535516","version":"1","preferredName":"Urine Protein Measurement Creatinine Ratio","longName":"6535516","preferredDefinition":"The determination of the amount of protein present in a urine sample.: The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.: Quotient of quantities of the same kind for different components within the same system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urine Protein Measurement","conceptCode":"C74760","definition":"The determination of the amount of protein present in a urine sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Creatinine","conceptCode":"C399","definition":"The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ratio","conceptCode":"C44256","definition":"Quotient of quantities of the same kind for different components within the same system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78CF9AB9-F372-79EF-E053-F662850A9E4F","latestVersionIndicator":"Yes","beginDate":"2018-10-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-22","modifiedBy":"ONEDATA","dateModified":"2018-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78CF9AB9-F38B-79EF-E053-F662850A9E4F","beginDate":"2018-10-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-22","modifiedBy":"ONEDATA","dateModified":"2018-10-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"313B97D8-5517-5B3C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-24","modifiedBy":"MORENOC","dateModified":"2018-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Which test was completed for eligibility?","url":null,"context":"Alliance"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32653064-82B6-372A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"MORENOC","dateModified":"2018-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}